UCLA-led study establishes link between early side effects from prostate cancer radiation and long-term side effects

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

Mailing a stool-based test directly to people’s homes was the most effective of four strategies for increasing colorectal cancer screening rates, according to a study by UCLA researchers aimed at identifying the best approach to promote CRC screening in adults ages 45 to 49.

August 08, 2025

Vol.51 No.31

In Brief

UIC, Northwestern, Moffitt researchers awarded $1.2M DOD grant for prostate cancer research

The U.S. Department of Defense Prostate Cancer Research Program has awarded the Data Science Award and a $1.2 million grant to researchers Charles Gaber, Natalie Reizine, Todd Lee, Lucia Petito, and Jessica Islam.

August 01, 2025

Vol.51 No.30

Clinical Roundup

Blood tests show potential for CRC detection, but follow-up falls short

About half patients completed a follow-up colonoscopy within six months of taking a blood-based colorectal cancer screening test, according to a study by investigators at UCLA Health Jonsson Comprehensive Cancer Center.

August 01, 2025

Vol.51 No.30

Clinical Roundup

Xtandi + ADT slow disease-progression in mHSPC compared to darolutamide + ADT

Xtandi (enzalutamide) plus ADT significantly slows disease progression vs darolutamide plus ADT in patients with mHSPC, according to a matching-adjusted indirect comparison analysis published in Future Oncology.

July 18, 2025

Vol.51 No.28

In Brief

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

July 11, 2025

Vol.51 No.27

UCLA-led study establishes link between early side effects from prostate cancer radiation and long-term side effects

YOU MAY BE INTERESTED IN

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

UIC, Northwestern, Moffitt researchers awarded $1.2M DOD grant for prostate cancer research

Blood tests show potential for CRC detection, but follow-up falls short

Xtandi + ADT slow disease-progression in mHSPC compared to darolutamide + ADT

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Renew today!

Subscriber content

Never miss an issue!

Login